Bacterial Gene Profiling to Predict Antibiotic Resistance During Cystic Fibrosis Pulmonary Exacerbations

Plain-language summary

This study looked at whether profiling the genes of bacteria could predict antibiotic resistance in patients hospitalized for a cystic fibrosis pulmonary exacerbation. To join, patients had to be 18 or older, chronically infected with Pseudomonas aeruginosa and/or Staphylococcus aureus, and able to produce sputum. It was conducted as a non-phase study and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

National Jewish Health

Start date

2/20/2020

Estimated completion

8/9/2024

Countries

United States

Related genes

Locations

• Denver, United States

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* CF patients 18 years or older who are hospitalized for IV treatment of an acute PEx
* Chronically infected with Pseudomonas aeruginosa and/or Staphylococcus aureus
* Can produce sputum
* Can provide written consent
* Willing to comply with study procedure

Exclusion Criteria:

* Subjects who are not colonized with Pseudomonas aeruginosa and/or Staphylococcus aureus
* The presence of a condition or abnormality that, in the opinion of the Principal Investigator, would compromise the safety of the patient or the quality of the data